Fernanda Augustini Rigon

Fernanda Augustini Rigon

Auto-generated profile, based on publicly available information

Fernanda Augustini Rigon

Graduate Program in Medical Sciences, Polydoro Ernani de São Thiago University Hospital, Federal University of Santa Catarina, Florianópolis, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2019 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
FRFernanda Augustini Rigon
Fernanda Augustini Rigon
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
AHAlexandre Hohl
Alexandre Hohl
SSSimone van de Sande-Lee
Simone van de Sande-Lee

3 June 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FRFernanda Augustini Rigon
Fernanda Augustini Rigon
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
AVAndré Gustavo Daher Vianna
André Gustavo Daher Vianna
LSLeonardo de Lucca Schiavon
Leonardo de Lucca Schiavon
AHAlexandre Hohl
Alexandre Hohl
SSSimone van de Sande-Lee
Simone van de Sande-Lee
The management of diabetes mellitus (DM) requires maintaining glycemic control, and patients must keep their blood glucose levels close to the normal range to reduce the risk of microvascular complications and cardiovascular events. While glycated hemoglobin (A1C) is currently the primary measure for glucose management and a key marker for long-term complications, it does not provide information on acute glycemic excursions and overall glycemic variability. These limitations may even be higher in some special situations, thereby compromising A1C accuracy, [...] ABSTRACT The management of diabetes mellitus (DM) requires maintaining glycemic control, and patients must keep their blood glucose levels close to the normal range to reduce the risk of microvascular complications and cardiovascular events. While glycated hemoglobin (A1C) is currently the primary measure for glucose management and a key marker for long-term complications, it does not provide information on acute glycemic excursions and overall glycemic variability. These limitations may even be higher in some special situations, thereby compromising A1C accuracy,

4 March 2024 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
FRFernanda Augustini Rigon
Fernanda Augustini Rigon
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
AHAlexandre Hohl
Alexandre Hohl
AVAndré Gustavo Daher Vianna
André Gustavo Daher Vianna
SSSimone van de Sande-Lee
Simone van de Sande-Lee
LSLeonardo de Lucca Schiavon
Leonardo de Lucca Schiavon
Aim: To evaluate the use of intermittently scanned continuous glucose monitoring (isCGM) in patients with liver cirrhosis (LC). Methods: Observational study including 30 outpatients with LC (Child-Pugh B/C): 10 without diabetes (DM) (G1), 10 with newly diagnosed DM by oral glucose tolerance test (G2), and 10 with a previous DM diagnosis (G3). isCGM (FreeStyle Libre Pro) was used for 56 days (four sensors/patient). Blood tests were performed at baseline and after 28 and 56 days. Results: No differences were found in the baseline characteristics, except for higher age in G3. There were significant differences between G1, G2 and G3 in glucose management indicator (GMI) (5.28 ± 0.17, 6.03 ± 0.59, 6.86 ± 1.08%, P < .001), HbA1c (4.82 ± 0.39, 5.34 ± 1.26, 6.97 ± 1.47%, P < .001), average glucose (82.79 ± 7.06, 113.39 ± 24.32, 149.14 ± 45.31mg/dL, P < .001), time in range (TIR) (70.89 ± 9.76, 80.2 ± 13.55, 57.96 ± 17.96%, P = .006), and glucose variability (26.1 ± 5.0, 28.21 ± 5.39, 35.31 ± 6.85%, P = .004). There was discordance between GMI and HbA1c when all groups were considered together, with a mean difference of 0.35% (95% SD 0.17, 0.63). In G1, the mean difference was 0.46% (95% SD 0.19, 0.73) and in G2 0.69% (95% SD 0.45, 1.33). GMI and HbA1c were concordant in G3, with a mean difference of −0.10 % (95% SD [−0.59, 0.38]). Conclusion: Disagreements were found between the GMI and HbA1c levels in patients with LC. isCGM was able to detect abnormalities in glycemic control that would not be detected by monitoring with HbA1c, suggesting that isCGM can be useful in assessing glycemic control in patients with LC.